The study of human umbilical cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in the treatment of spinal cord injury

Objective:To explore the effect of human umbilical cord mononuclear cells and human umbilical cord mesenchymal stem cells (MSCs) transplantation on injured spinal cord function and to find a better source of cells for the treatment of spinal cord injury(SCI).Method:Human umbilical cord blood and human umbilical cords were collected,and mononuclear cells and MSCs were derived.The rat SCI models were divided into 3 groups:SCI model plus mononuclear cells transplantation group,SCI model plus mesenchymal stem cells transplantation group and SCI model plus L-DMEM group.Immunohistochemistry and immunofluorescence were used to determine the survival and migration of implanted cells in spinal cord 1—4 weeks after transplantation.Basso-Beattie-Brasnahan (BBB) scale system was applied to assess the function recovery of spinal cord.Result:There was no significant difference in postoperative score at each time point in SCI model plus DMEM group.The function of spinal cord became better in SCI model plus cells transplantation groups,and there were significant differences compared with SCI model plus DMEM group.The function of spinal cord in SCI model plus mononuclear cells transplantation group was better than that in SCI model plus MSC transplantation group,and the difference was prominently.Conclusion:Compared with MSCs,human umbilical cord blood mononuclear cells were more suitable as a source of cells for the treatment of SCI.